Johnson & Johnson (NYSE:JNJ) Shares Sold by Trust Co. of Oklahoma

Trust Co. of Oklahoma cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.0% in the third quarter, HoldingsChannel.com reports. The fund owned 3,221 shares of the company’s stock after selling 100 shares during the period. Trust Co. of Oklahoma’s holdings in Johnson & Johnson were worth $522,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the stock. Richardson Financial Services Inc. acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $54,000. PVG Asset Management Corp raised its position in shares of Johnson & Johnson by 28.8% in the fourth quarter. PVG Asset Management Corp now owns 3,899 shares of the company’s stock valued at $611,000 after buying an additional 872 shares during the last quarter. Sivia Capital Partners LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $592,000. Golden Road Advisors LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $238,000. Finally, Ables Iannone Moore & Associates Inc. acquired a new stake in Johnson & Johnson during the fourth quarter worth about $2,300,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 1.3 %

Shares of NYSE:JNJ traded up $2.18 during trading on Tuesday, hitting $163.78. 6,605,306 shares of the company were exchanged, compared to its average volume of 7,031,943. The stock has a market capitalization of $394.17 billion, a P/E ratio of 10.07, a PEG ratio of 2.65 and a beta of 0.52. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85. The firm’s 50 day moving average price is $162.60 and its 200-day moving average price is $154.48.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The firm had revenue of $22.45 billion during the quarter, compared to the consensus estimate of $22.33 billion. During the same quarter in the prior year, the firm earned $2.80 EPS. Johnson & Johnson’s revenue for the quarter was up 4.3% on a year-over-year basis. On average, research analysts predict that Johnson & Johnson will post 10 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.03%. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of analyst reports. Sanford C. Bernstein lifted their target price on shares of Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Morgan Stanley lifted their target price on shares of Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 18th. TD Cowen reduced their target price on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a research note on Thursday, July 18th. The Goldman Sachs Group reduced their target price on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research note on Friday, July 19th. Finally, Daiwa America cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Six equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $174.31.

Insider Activity at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is owned by insiders.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.